RE:RE:RE:RE:Buying opportunity for insiders..."Insiders are the proof that everyone can use as the evidence that Gagnon is useless..."
Insiders are putting it all on Gagnon's programs with a record ~$6-$7 million committed to the avenanthramide clinical trial, avenanthramide malting technology scale-up, and PGX scale-up. In addition there is also the 'go / no go' decision for the fibrosis clinical trial upon us which could be a considerable cost. The insiders are going big on Gagnon's vision and if they are wrong their shares and options will suffer big time. They could have also spend their time elsewhere.